domingo, 26 de julio de 2015

Genomics|Genetic Testing|Guidelines: Pharmacogenomics

Genomics|Genetic Testing|Guidelines

Genomics & Health Impact Update banner with DNA in background



Pharmacogenomics



GuidelineOrganizationPublished
HLA-B*15:02 and HLA-A*31:01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactionsExternal Web Site IconCanadian Pharmacogenomics Network for Drug Safety Clinical Recommendation GroupExternal Web Site Icon2014
CYP2C9 and HLA-B genotypes and phenytoin dosingExternal Web Site IconClinical Pharmacogenetics Implementation ConsortiumExternal Web Site Icon2014
Cytochrome P450 2D6 genotype and codeine therapy - 2014 updateExternal Web Site IconClinical Pharmacogenetics Implementation ConsortiumExternal Web Site Icon2014
HLA-B Genotype and Abacavir Dosing - 2014 updateExternal Web Site IconClinical Pharmacogenetics Implementation ConsortiumExternal Web Site Icon2014
IFNL3 (IL28B) genotype and PEG interferon-α-based regimensExternal Web Site IconClinical Pharmacogenetics Implementation ConsortiumExternal Web Site Icon2014
Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development processExternal Web Site IconClinical Pharmacogenetics Implementation ConsortiumExternal Web Site Icon2014
Ivacaftor therapy in the context of CFTR genotypeExternal Web Site IconClinical Pharmacogenetics Implementation ConsortiumExternal Web Site Icon2014
Rasburicase therapy in the context of G6PD deficiency genotypeExternal Web Site IconClinical Pharmacogenetics Implementation ConsortiumExternal Web Site Icon2014
SLCO1B1 and simvastatin-induced myopathy - 2014 updateExternal Web Site IconClinical Pharmacogenetics Implementation ConsortiumExternal Web Site Icon2014
Testing and clinical management issues associated with HLA and non-HLA antibodies in transplantationExternal Web Site IconAustralian expert panel2013
CYP2D6 genotyping for safe and efficacious codeine therapyExternal Web Site IconCanadian Pharmacogenomics Network for Drug Safety Clinical Recommendation GroupExternal Web Site Icon2013
CYP2C19 genotype and clopidogrel therapy - 2013 updateExternal Web Site IconClinical Pharmacogenetics Implementation ConsortiumExternal Web Site Icon2013
CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressantsExternal Web Site IconClinical Pharmacogenetics Implementation ConsortiumExternal Web Site Icon2013
Dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosingExternal Web Site IconClinical Pharmacogenetics Implementation ConsortiumExternal Web Site Icon2013
HLA-B genotype and carbamazepine dosingExternal Web Site IconClinical Pharmacogenetics Implementation ConsortiumExternal Web Site Icon2013
Human leukocyte antigen-B genotype and allopurinol dosingExternal Web Site IconClinical Pharmacogenetics Implementation ConsortiumExternal Web Site Icon2013
Thiopurine methyltransferase genotype and thiopurine dosing - 2013 updateExternal Web Site IconClinical Pharmacogenetics Implementation ConsortiumExternal Web Site Icon2013
SLCO1B1 and simvastatin-induced myopathyExternal Web Site IconClinical Pharmacogenetics Implementation ConsortiumExternal Web Site Icon2012
Testing for cytochrome P450 polymorphisms in adults with nonpsychotic depression treated with selective serotonin reuptake inhibitorsExternal Web Site IconEvaluation of Genomic Applications in Practice and PreventionExternal Web Site Icon2007

No hay comentarios:

Publicar un comentario